Table 2. . Baseline clinical characteristics.
| Characteristics | Number |
|---|---|
| Age at the time of treatment | |
| Median (range) | 61 (39–83) years |
| Age category (years) | |
| <65 | 10 |
| 65–75 | 5 |
| >75 | 2 |
| Sex | |
| Male | 3 |
| Female | 14 (82.3%) |
| ECOG performance status | |
| 0 | 5 |
| 1 | 12 |
| Site of primary | |
| Head and neck | 5 |
| Vulvovaginal | 6 |
| Anorectal/GI | 6 |
| M stage | |
| M0 | 2 |
| M1a/M1b | 1 |
| M1c | 14 |
| LDH | |
| ≤ULN | 8 |
| >1–2 × ULN | 7 |
| >2 × ULN | 2 |
| Brain metastases | |
| Yes | 1 |
| No | 16 |
| Liver metastases | |
| Yes | 7 |
| No | 10 |
| Mutations | |
| BRAF | 0 |
| KIT | 1 |
| NRAS | 2 |
| Wild-type | 12 |
| Unknown | 2 |
| Prior systemic therapy | |
| Yes | 6 |
| No | 11 |
ECOG: European Cooperative Oncology Group; GI: Gastrointestinal; LDH: Lactate dehydrogenase; ULN: Upper limit of normal.